Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
RSS SUMMARY · AGGREGATED FROM TWSJ
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
World News
Israel Built and Defended a Secret Iran War Base in Iraq
TWSJ·5h ago·3 min read
Tech
For Palantir, AI Is a Product, a Punching Bag—and a Problem
TWSJ·7h ago·3 min read
World News
The Hunter-Gatherers Weighing Whether to Join the Modern World
TWSJ·8h ago·3 min read
Business
Person Struck and Killed by Plane on Runway at Denver Airport
TWSJ·9h ago·3 min read
Related
On this beat
Business
RBC revamps S&P 500 target for the rest of 2026
THE STREET·1h ago·3 min read
Business
Wedbush sends blunt message on Elon Musk’s Tesla and Intel deal
THE STREET·1h ago·3 min read
Business
Target’s genuine suede clog slippers are only $24
THE STREET·2h ago·3 min read
Business
Louis Navellier sends powerful message on AI FOMO trade, economy
THE STREET·2h ago·3 min read